Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Schwendinger, Michael G ^a   O'Rourke, Maria ^a   Traweger, Andreas ^a,b   Savidis Dacho, Helga ^a   Pilz, Andreas ^a   Portsmouth, Daniel ^a   Livey, Ian ^a   Barrett, P Noel ^a   Crowe, Brian A ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNOGLOBULIN G; LIPOPROTEINS; LYME DISEASE; LYME DISEASE VACCINES; MICE; VACCINATION;

EID: 84894146944     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079022     Document Type: Article

References (41)

1. Stanek G, Wormser GP, Gray J, Strle F (2012) Lyme borreliosis. Lancet 379: 461-473.
2. Steere AC, Livey I (2012) Lyme disease vaccines. 1122-1132.
3. Adams DA, Gallagher KM, Jajosky RA, Kriseman J, Sharp P, et al. (2013) Summary of Notifiable Diseases - United States, 2011. MMWR Morb Mortal Wkly Rep 60: 1-117.
4. Lindgren E, Jaenson TGT (2006) Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. WHO Europe website. Available: http://www.euro.who.int/document/E89522.pdf. Accessed 2013 Sep 30.
5. Stanek G, Reiter M (2011) The expanding Lyme Borrelia complex-clinical significance of genomic species? Clin Microbiol Infect 17: 487-493.
6. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, et al. (1998) A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 339: 216-222. (Pubitemid 28350163)
7. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, et al. (1998) Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 339: 209-215. (Pubitemid 28350162)
8. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, et al. (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281: 703-706. (Pubitemid 28390407)
9. Steere AC, Drouin EE, Glickstein LJ (2011) Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 52 Suppl 3: s259-s265.
10. Plotkin SA (2011) Correcting a public health fiasco: The need for a new vaccine against Lyme disease. Clin Infect Dis 52 Suppl 3: s271-s275.
11. Poland GA (2011) Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis 52 Suppl 3: s253-s258.
12. Gern L, Hu CM, Voet P, Hauser P, Lobet Y (1997) Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine 15: 1551-1557. (Pubitemid 27402138)
13. Golde WT, Burkot TR, Piesman J, Dolan MC, Capiau C, et al. (1995) The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Vaccine 13: 435-441.
14. Lovrich SD, Callister SM, DuChateau BK, Lim LC, Winfrey J, et al. (1995) Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect Immun 63: 2113-2119.
15. Wressnigg N, Pollabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, et al. (2013) Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase I/II clinical trial. Lancet Infect Dis .
16. Clinical trials.gov website. Phase 1/2 Lyme Vaccine Study. Available: http://clinicaltrials.gov/ct2/show/NCT01504347 . Accessed 2013 Sep 30.
17. Livey I, O'Rourke M, Traweger A, Savidis-Dacho H, Crowe BA, et al. (2011) A new approach to a Lyme disease vaccine. Clin Infect Dis 52 Suppl 3: s266-s270.
18. Fuchs H, Wallich R, Simon MM, Kramer MD (1994) The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor. Proc Natl Acad Sci U S A 91: 12594-12598.
19. Coleman JL, Gebbia JA, Piesman J, Degen JL, Bugge TH, et al. (1997) Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 89: 1111-1119. (Pubitemid 127678744)
20. Pal U, Montgomery RR, Lusitani D, Voet P, Weynants V, et al. (2001) Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J Immunol 166: 7398-7403. (Pubitemid 32525616)
21. Hovius JW, van Dam AP, Fikrig E (2007) Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol 23: 434-438. (Pubitemid 47271975)
22. Battisti JM, Bono JL, Rosa PA, Schrumpf ME, Schwan TG, et al. (2008) Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector. Infect Immun 76: 5228-5237.
23. Feder HM Jr, Beran J, Van Hoecke C, Abraham B, De Clercq N, et al. (1999) Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. J Pediatr 135: 575-579.
24. Schoen RT, Sikand VK, Caldwell MC, Van Hoecke C, Gillet M, et al. (2000) Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clin Ther 22: 315-325. (Pubitemid 30213137)
25. Schoen RT, Deshefy-Longhi T, Van Hoecke C, Buscarino C, Fikrig E (2003) An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clin Ther 25: 210-224. (Pubitemid 36206747)
26. Sikand VK, Halsey N, Krause PJ, Sood SK, Geller R, et al. (2001) Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 108: 123-128. (Pubitemid 32592015)
27. Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
28. Luke CJ, Marshall MA, Zahradnik JM, Bybel M, Menefee BE, et al. (2000) Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both. J Infect Dis 181: 1062-1068. (Pubitemid 30194493)
29. Probert WS, LeFebvre RB (1994) Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect Immun 62: 1920-1926. (Pubitemid 24136997)
30. Aydintug MK, Gu Y, Philipp MT (1994) Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey. Infect Immun 62: 4929-4937. (Pubitemid 24332798)
31. Golde WT, Piesman J, Dolan MC, Kramer M, Hauser P, et al. (1997) Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 65: 882-889. (Pubitemid 27087986)
32. Johnson BJ, Sviat SL, Happ CM, Dunn JJ, Frantz JC, et al. (1995) Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 13: 1086-1094.
33. Kurtenbach K, Dizij A, Voet P, Hauser P, Simon MM (1997) Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Vaccine 15: 1670-1674. (Pubitemid 27445746)
34. Creson JR, Lim LC, Glowacki NJ, Callister SM, Schell RF (1996) Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting. Clin Diagn Lab Immunol 3: 184-190. (Pubitemid 26103754)
35. Liu YF, Lim LC, Schell K, Lovrich SD, Callister SM, et al. (1994) Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry. Clin Diagn Lab Immunol 1: 145-149. (Pubitemid 2057590)
36. O'Rourke M, Traweger A, Lusa L, Stupica D, Maraspin V, et al. (2013) Quantitative Detection of Borrelia burgdorferi sensu lato in Erythema Migrans Skin Lesions Using Internally Controlled Duplex Real Time PCR. PLoS One 8: e63968.
37. Sadziene A, Thompson PA, Barbour AG (1993) In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis 167: 165-172. (Pubitemid 23002852)
38. Sadziene A, Barbour AG (1995) [Growth inhibition of Borrelia burgdorferi sensu lato by antibodies. A contribution to understanding the pathogenesis and improving diagnosis of Lyme borreliosis]. Wien Med Wochenschr 145: 162-165.
39. Crippa M, Rais O, Gern L (2002) Investigations on the mode and dynamics of transmission and infectivity of Borrelia burgdorferi sensu stricto and Borrelia afzelii in Ixodes ricinus ticks. Vector Borne Zoonotic Dis 2: 3-9.
40. Lebet N, Gern L (1994) Histological examination of Borrelia burgdorferi infections in unfed Ixodes ricinus nymphs. Experimental & Applied Acarology 18: 177-183.
41. Leuba-Garcia S, Kramer MD, Wallich R, Gern L (1994) Characterization of Borrelia burgdorferi isolated from different organs of Ixodes ricinus ticks collected in nature. Zentralbl Bakteriol 280: 468-475. (Pubitemid 2068444)